These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26946961)

  • 1. Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.
    Gao X; Xue A; Fang Y; Shu P; Ling J; Qin J; Hou Y; Shen K; Sun Y; Qin X
    Sci Rep; 2016 Mar; 6():22840. PubMed ID: 26946961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
    Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP
    Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors.
    Wada N; Takahashi T; Kurokawa Y; Nakajima K; Nishida T; Koh M; Akamaru Y; Motoori M; Kimura Y; Tanaka K; Miyazaki Y; Makino T; Yamasaki M; Eguchi H; Doki Y
    Surg Today; 2021 Sep; 51(9):1506-1512. PubMed ID: 33570662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry.
    Sato S; Tsujinaka T; Masuzawa T; Yamamoto K; Takahashi T; Yamashita Y; Fujita J; Takagi M; Hirota S; Nishida T
    Surg Today; 2017 Jan; 47(1):58-64. PubMed ID: 27194124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S
    Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.
    Cho H; Ryu MH; Lee Y; Park YS; Kim KH; Kim JH; Park Y; Lee SM; Kim CW; Kim BS; Yoo MW; Kang YK
    Oncologist; 2019 Dec; 24(12):e1443-e1449. PubMed ID: 31315961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
    Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH
    J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
    Sutton TL; Walker BS; Billingsley KG; Sheppard BC; Corless CL; Heinrich MC; Mayo SC
    Surgery; 2021 Nov; 170(5):1481-1486. PubMed ID: 34090672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
    Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry.
    Sato S; Tsujinaka T; Yamamoto K; Takahashi T; Kishi K; Imamura H; Fujita J; Takagi M; Hirota S; Nishida T
    Surg Today; 2016 Sep; 46(9):1068-75. PubMed ID: 26611538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year review of gastrointestinal stromal tumours at a tertiary referral hospital in New Zealand.
    Siu J; Lim M; Fischer J; Dobbs B; Wakeman C; Ing A; Frizelle F
    ANZ J Surg; 2016 Mar; 86(3):162-6. PubMed ID: 24325620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study.
    Seesing MF; Tielen R; van Hillegersberg R; van Coevorden F; de Jong KP; Nagtegaal ID; Verhoef C; de Wilt JH;
    Eur J Surg Oncol; 2016 Sep; 42(9):1407-13. PubMed ID: 27038995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery offers prognostic benefits in metastatic gastrointestinal stromal tumors with generalized progression following imatinib therapy: a single institute retrospective study.
    Liu DN; Jia WW; Wang HY; Wu JH; Li CP; Hao CY
    BMC Surg; 2023 Jul; 23(1):189. PubMed ID: 37403109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis.
    Ling JY; Ding MM; Yang ZF; Zhao YD; Xie XY; Shi LS; Wang HM; Cao WT; Zhang JW; Hu HB; Cai Y; Wang H; Deng YH
    J Surg Oncol; 2021 Dec; 124(8):1442-1450. PubMed ID: 34494280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.